NCT01380938

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date: Oct 1, 2010
Primary completion: Aug 1, 2012
Completion date: Aug 1, 2012
First posted: —
Last posted: —
Enrollment: 1150
Arms / groups: 3 / —
Source: AACT · pre-existing

Sponsors

Casa Sollievo della Sofferenza IRCCSLead sponsor
Azienda Ospedaliera V. CervelloCollaborator
University of PalermoCollaborator
Campus Bio-Medico UniversityCollaborator
University of FlorenceCollaborator
University of BariCollaborator
Azienda Ospedaliera Antonio CardarelliCollaborator
University of PaviaCollaborator
Azienda Ospedaliera San Camillo ForlaniniCollaborator
University of SassariCollaborator
Casa di Cura Mater DeiCollaborator
Ospedale Francesco FerrariCollaborator
Ospedale di VenosaCollaborator
Ospedale R. Dimiccoli, BarlettaCollaborator
Ospedale Civile Vittorio Emanuele II, BisceglieCollaborator
Ospedale Civile Spirito SantoCollaborator
Ospedale di Canosa di PugliaCollaborator
Ospedale Sandro Pertini, RomaCollaborator
Ospedale di MottolaCollaborator
Ospedale Santa Caterina Novella, GalatinaCollaborator
Ospedale Valduce, ComoCollaborator
Azienda Ospedaliera, SiracusaCollaborator
Azienda Ospedaliera, LuccaCollaborator
University of FoggiaCollaborator
University of FerraraCollaborator
University of TurinCollaborator
University of CataniaCollaborator
San Giuseppe Moscati HospitalCollaborator
Casa Sollievo della Sofferenza IRCCSReponsible party - principal investigator
Vita-Salute University of Milano. ItalyStudy director
Vita-Salute University of Milano. ItalyCollaborator

Drugs studied

Indications studied

Hepatitis, Chronic

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.